摘要
激素抵抗性前列腺癌的治疗是前列腺癌治疗中的重点与难点,各种治疗方法层出不穷,但真正能延长生存的治疗方法并不多。多西他赛联合强的松方案已经成为治疗前列腺癌的一线化疗方案,唑来膦酸能明显减少骨相关事件的发生率,生物靶向治疗在前列腺癌中的研究正热,已有许多有效的研究报道,进一步确切的疗效评估有待大样本研究证实。
Treatment of hormonal refractory prostate cancer（HRPC） is nowadays a challenge in the clinical practice,as there are few effective therapies to lengthen patients＇ life.So far,Docetaxel plus Prednisone has been confirmed to be the first line regimen,Zoladronic acid has been demonstrated to be efficacious in reducing bone related events,and targeted therapy is currently under intensive investigation for HRPC treatment with effective results shown.Confirmation of the efficacy of these regimens needs further studies with larger samples
出处
《现代泌尿外科杂志》
CAS
2011年第1期6-9,共4页
Journal of Modern Urology
关键词
激素抵抗
前列腺癌
化疗
生物治疗
hormone refractory
prostate cancer
chemotherapy
biotherapy
